WireMinute
Health15 November 2026

Common Diabetes Drug Metformin Linked to Lower Death Risk After Covid, Study Finds

People with type 2 diabetes who were taking the common drug metformin before catching Covid-19 were far more likely to still be alive a year later than patients on a different diabetes drug, new research suggests.

Common Diabetes Drug Metformin Linked to Lower Death Risk After Covid, Study Finds

Researchers at Stanford University examined medical records for 53,332 adults living with type 2 diabetes who caught Covid-19 between October 2021 and November 2023. Most of them, 50,965 people, had been prescribed metformin at least a month before their diagnosis, while 2,367 were taking a different class of diabetes drug known as DPP-4 inhibitors. After adjusting for age, sex and other factors, the team found the metformin group were 39 percent less likely to die in the year after their infection.

The findings were published in the journal Diabetes, Obesity and Metabolism. Metformin is the drug doctors usually prescribe first for type 2 diabetes: it brings blood sugar down and helps the body respond better to insulin. The researchers said it was not yet clear whether those effects explained the survival gap, and the results point to protective effects that go beyond blood-sugar control.

An early signal that metformin users also developed fewer long-Covid symptoms, about 13 percent lower at first glance, did not survive further statistical testing, the researchers said. The new analysis lines up with earlier work from the University of Minnesota, which found patients given metformin within six days of a Covid diagnosis were less likely to die or develop long Covid.

The study cannot show that the drug itself was behind the survival difference, because it looked back at existing medical records rather than running a clinical trial. Independent experts urged caution, saying the evidence is too thin to justify changing anyone's treatment and that patients should not switch drugs on the basis of the findings. Randomised trials are still needed to confirm whether the drug offers real protection after infection.

Key points

Read on WireMinute
WireMinute - News, updated every minute. More headlines